Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.

摘要: Carboplatin (Carbo-Pt), an alkylating agent cleared from the plasma through glomerular filtration, is commonly used for treatment of ovarian cancer. When administered at high dosage or to patients with reduced renal function, Carbo-Pt may be nephrotoxic. The dose calculated Calvert formula, using value 24-hour creatinine clearance (24h Ccr) as estimate filtration rate (GFR). aim this study was evaluate possibility individualizing alternative method GFR, based on body composition analysis, and then assess nephrotoxicity therapy individualized new method. First, we evaluated agreement between GFR (renal diethylene triamine pentaacetic acid ( 99m Tc-DTPA)), 24h Ccr, BCM GFR) basis individual values cell mass (BCM) creatinine. gave a better than Ccr. Then, combination chemotherapy (AUC 5-6 ) in 23 affected by adjusted residual function patients, GFR. No case acute failure observed regimen. Urinary excretion proteins (albumin, p2-microglobulin, retinol-binding protein) tubular enzymes, measured markers damage, increased significantly transiently only first days after chemotherapy, whereas no evidence chronic nephrotoxic effect documented. Dose individualization, minimize due therapy.